Cargando…

Drug Repurposing on G Protein-Coupled Receptors Using a Computational Profiling Approach

G protein-coupled receptors (GPCRs) are the largest human membrane receptor family regulating a wide range of cell signaling. For this reason, GPCRs are highly desirable drug targets, with approximately 40% of prescribed medicines targeting a member of this receptor family. The structural homology o...

Descripción completa

Detalles Bibliográficos
Autores principales: de Felice, Alessandra, Aureli, Simone, Limongelli, Vittorio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138314/
https://www.ncbi.nlm.nih.gov/pubmed/34026848
http://dx.doi.org/10.3389/fmolb.2021.673053
_version_ 1783695779850878976
author de Felice, Alessandra
Aureli, Simone
Limongelli, Vittorio
author_facet de Felice, Alessandra
Aureli, Simone
Limongelli, Vittorio
author_sort de Felice, Alessandra
collection PubMed
description G protein-coupled receptors (GPCRs) are the largest human membrane receptor family regulating a wide range of cell signaling. For this reason, GPCRs are highly desirable drug targets, with approximately 40% of prescribed medicines targeting a member of this receptor family. The structural homology of GPCRs and the broad spectrum of applications of GPCR-acting drugs suggest an investigation of the cross-activity of a drug toward different GPCR receptors with the aim of rationalizing drug side effects, designing more selective and less toxic compounds, and possibly proposing off-label therapeutic applications. Herein, we present an original in silico approach named “Computational Profiling for GPCRs” (CPG), which is able to represent, in a one-dimensional (1D) string, the physico-chemical properties of a ligand–GPCR binding interaction and, through a tailored alignment algorithm, repurpose the ligand for a different GPCR. We show three case studies where docking calculations and pharmacological data confirm the drug repurposing findings obtained through CPG on 5-hydroxytryptamine receptor 2B, beta-2 adrenergic receptor, and M2 muscarinic acetylcholine receptor. The CPG code is released as a user-friendly graphical user interface with numerous options that make CPG a powerful tool to assist the drug design of GPCR ligands.
format Online
Article
Text
id pubmed-8138314
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81383142021-05-22 Drug Repurposing on G Protein-Coupled Receptors Using a Computational Profiling Approach de Felice, Alessandra Aureli, Simone Limongelli, Vittorio Front Mol Biosci Molecular Biosciences G protein-coupled receptors (GPCRs) are the largest human membrane receptor family regulating a wide range of cell signaling. For this reason, GPCRs are highly desirable drug targets, with approximately 40% of prescribed medicines targeting a member of this receptor family. The structural homology of GPCRs and the broad spectrum of applications of GPCR-acting drugs suggest an investigation of the cross-activity of a drug toward different GPCR receptors with the aim of rationalizing drug side effects, designing more selective and less toxic compounds, and possibly proposing off-label therapeutic applications. Herein, we present an original in silico approach named “Computational Profiling for GPCRs” (CPG), which is able to represent, in a one-dimensional (1D) string, the physico-chemical properties of a ligand–GPCR binding interaction and, through a tailored alignment algorithm, repurpose the ligand for a different GPCR. We show three case studies where docking calculations and pharmacological data confirm the drug repurposing findings obtained through CPG on 5-hydroxytryptamine receptor 2B, beta-2 adrenergic receptor, and M2 muscarinic acetylcholine receptor. The CPG code is released as a user-friendly graphical user interface with numerous options that make CPG a powerful tool to assist the drug design of GPCR ligands. Frontiers Media S.A. 2021-05-07 /pmc/articles/PMC8138314/ /pubmed/34026848 http://dx.doi.org/10.3389/fmolb.2021.673053 Text en Copyright © 2021 de Felice, Aureli and Limongelli. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
de Felice, Alessandra
Aureli, Simone
Limongelli, Vittorio
Drug Repurposing on G Protein-Coupled Receptors Using a Computational Profiling Approach
title Drug Repurposing on G Protein-Coupled Receptors Using a Computational Profiling Approach
title_full Drug Repurposing on G Protein-Coupled Receptors Using a Computational Profiling Approach
title_fullStr Drug Repurposing on G Protein-Coupled Receptors Using a Computational Profiling Approach
title_full_unstemmed Drug Repurposing on G Protein-Coupled Receptors Using a Computational Profiling Approach
title_short Drug Repurposing on G Protein-Coupled Receptors Using a Computational Profiling Approach
title_sort drug repurposing on g protein-coupled receptors using a computational profiling approach
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138314/
https://www.ncbi.nlm.nih.gov/pubmed/34026848
http://dx.doi.org/10.3389/fmolb.2021.673053
work_keys_str_mv AT defelicealessandra drugrepurposingongproteincoupledreceptorsusingacomputationalprofilingapproach
AT aurelisimone drugrepurposingongproteincoupledreceptorsusingacomputationalprofilingapproach
AT limongellivittorio drugrepurposingongproteincoupledreceptorsusingacomputationalprofilingapproach